Nonadherence in Nearly One-Third of Patients With HTN

Share this content:
Nonadherence in Nearly One-Third of Patients With HTN
Nonadherence in Nearly One-Third of Patients With HTN

MONDAY, Nov. 7, 2016 (HealthDay News) -- More than 30 percent of patients with hypertension are not adherent to antihypertensive drug therapy, according to a study published online Nov. 3 in the Journal of Evaluation in Clinical Practice.

Jerome J. Federspiel, M.D., Ph.D., from the University of North Carolina at Chapel Hill, and colleagues linked Atherosclerosis Risk in Communities records to Medicare claims for cohort participants reporting hypertension without prevalent cardiovascular disease. Medicare Part D claims data were used to assess antihypertensive medication adherence, measured as more than 80 percent proportion days covered.

The researchers found that for 31.5 percent of the 1,826 participants with hypertension and Part D coverage there was no antihypertensive class with medication adherence of more than 80 percent proportion days covered in the three months preceding the report of hypertension. Positive predictors of use included female gender and diabetes, after adjustment for confounding variables; African-American race and current smoking were negative predictors. After adjustment, the correlation between receiving no therapy and a composite end point of cardiovascular outcomes through 2012 was not statistically significant; the adjusted associations with Medicare inpatient days or payments were also not statistically significant.

"Despite having medical and prescription coverage, nearly a third of hypertensive participants were not adherent to antihypertensive drug therapy," the authors write. "Differences in clinical outcomes associated with nonadherence, though not statistically significant, were consistent with results from randomized trials."

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

ASH: Synthetic Blood Cell Passes Proof-of-Concept Testing

ASH: Synthetic Blood Cell Passes Proof-of-Concept Testing

Synthetic product made from purified human hemoglobin proteins coated with a synthetic polymer

Fewer School Shootings in States With Tighter Gun Laws

Fewer School Shootings in States With Tighter Gun ...

Study also found that states that spent more money on mental health care, education saw less violence

SABCS: No Survival Benefit Seen for Letrozole Beyond Five Years

SABCS: No Survival Benefit Seen for Letrozole Beyond ...

Study found women who continued with letrozole did experience other benefits, however

is free, fast, and customized just for you!

Already a member?

Sign In Now »